Latest Articles
-
Leverage To Be A Challenge For Abbott, Once Deals Close: Part 2
In the Part 1 we discussed how levered Abbott (NYSE: ABT) would once its has completed the acquisitions of both acquisition of St. Jude (NYSE: STJ) and Alere (NYSE: ALR). In this article we look at some of the possible ways in which the company m...
-
Why Did Abbott’s Stock Plummet Recently?
Over the last one month, Abbott ’s (NYSE: ABT) stock has declined more than 10%. The market has been relatively benign during this period, with the mean daily return totalling 1.8% for NYSE index, -2% for S&P 500 and -1.8% for DJIA. We believ...
-
Making Sense of Abbott’s Sale Of Its Optics Business
Abbott (NYSE: ABT) is selling its medical optics division to J&J (NYSE: JNJ), subject to customary approval, in an all cash deal valued at $4.3 billion. According to Abbott, the move is aimed at narrowing the company’s focus and building its...
-
Leverage To Be A Challenge For Abbott, Once Deals Close: Part 1
Abbott (NYSE: ABT) is about to acquire St. Jude Medical (NYSE: STJ), subject to regulatory approval, at a premium of 37%. The deal is valued at about $25 billion. In enterprise value basis, the transaction is valued at around $30 billion. Meanwhi...
-
Recent Product Launches Drive Growth For Abbott Laboratories In Q2’16
Leading healthcare major, Abbott Laboratories (NYSE:ABT) reported its Q2 2016 earnings on July 20, 2016. The company’s sales for the quarter grew by 6.4% excluding the unfavorable impact of 3.2% due to foreign currency headwinds. The forei...
-
What Can We Expect From Abbott’s Q2’16 Earnings?
Abbott Laboratories (NYSE:ABT) is set to announce its Q2’16 earnings on July 20th. In Q1’16, despite a strong operating growth, the company’s key metrics declined due to currency headwinds. Abbott’s net income and EPS fi...
-
Why Is The FDA Approval Of Absorb Significant For Abbott?
The recent FDA approval of Abbott’s (NYSE:ABT) fully absorbable stent-Absorb, which is used to treat the coronary artery disease, is a significant breakthrough for the company. The following are the key reasons as to why this is significa...
-
Why Is The St. Jude Acquistion A Risky Bet For Abbott?
The St. Jude acquisition announced by Abbott (NYSE:ABT) is expected to provide significant synergies and the much needed growth for Abbott. However, this merger sets off alarm bells for Abbott’s investors, as the company will have to take...
-
How Important Are Emerging Markets To Abbott?
Abbott derives approximately 50% of its sales from emerging markets. This is one key reason as to why Abbott’s sales are largely affected due to foreign currency fluctuations. The company’s sales declined by 8.3% or $1680 million in 2...
-
Why Is Abbott Acquiring St. Jude?
In one of the most prodigious health-care deals in recent memory, Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire St. Jude Medical (NYSE: STJ) for $25 billion. In this analysis, we analyse the key reasons as to why ...
-
What is Abbott’s Revenue And Gross Profit Breakdown?
See the links below for more information and analysis about Abbott: What’s Abbott’s Fundamental Value Based On Expected 2016 Results? By What Percentage Did Abbott’s Revenue & Gross Profits Grow In The Last 5 Years? ...
-
Abbott Earnings Review: Foreign Currency Effects Subdue An Otherwise Strong Operational Growth
Leading healthcare major, Abbott Laboratories (NYSE:ABT) reported its Q1 2016 earnings on April 20, 2016. Despite a strong operating growth, led by the established pharmaceutical division in key emerging markets, Abbott’s key metrics decli...
-
What Can We Expect From Abbott’s Q1’16 Earnings?
Leading healthcare major, Abbott Laboratories is set to announce its Q1 2016 results on April 20, 2016. A stronger U.S dollar (relative to emerging markets currencies) and a challenging economic environment in Venezuela had together weighed down ...
-
What’s Abbott’s Fundamental Value Based On Expected 2016 Results?
See the links below for more information and analysis about Abbott: What is Abbott’s Revenue And Gross Profit Breakdown? By What Percentage Did Abbott’s Revenue & Gross Profits Grow In The Last 5 Years? Notes:
-
How Has Abbott’s Revenue Mix Changed In The Last 5 Years?
Nutritional and diagnostics have become an increasingly important segment for Abbott over the last five years. Sales from pharmaceutical products declined in 2012 due to the spin-off of Abbott’s proprietary pharmaceutical drugs business i...
